​

Funding Round

Series A - Exsilio Therapeutics

Series A - Exsilio Therapeutics

Investment Firm

Overview

Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.

Announced Date

Jun 25, 2024

Funding Type

Series A

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a early_stage_venture and late_stage_venture and post_ipo and seed firm.

Delos Capital

Delos Capital

Delos Capital is a late_stage_venture and private_equity firm.

Participant Investors

11

Investor Name
Participant InvestorInnovation Endeavors
Participant InvestorNovartis Venture Fund
Participant InvestorCRISPR Therapeutics
Participant InvestorInvus
Participant InvestorInsight Partners

Round Details and Background

Exsilio Therapeutics raised $82000000 on 2024-06-25 in Series A

Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.

Company Funding History

1

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 25, 2024
Series A - Exsilio Therapeutics
11-82.0M

Recent Activity

There is no recent news or activity for this profile.